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i.org/1infarction (STEMI) has been associated with adverse outcome. However, little is known
about the development of increased SPAP after STEMI treated with primary percutaneous
coronary intervention. The aims of this study were to investigate the incidence and de-
terminants of elevated SPAP (SPAP ‡36 mm Hg at 12 months) after ﬁrst STEMI and to
analyze its prognostic implications. A total of 705 patients (60 – 12 years; 75% men; left
ventricular ejection fraction [LVEF] 47 – 9%) with ﬁrst STEMI treated with primary
percutaneous coronary intervention were evaluated. Two-dimensional echocardiography
was available at baseline and 12-month follow-up. Data on all-cause mortality were
collected at long-term follow-up. Incident elevated SPAP was present in 5% (n [ 38) of
patients. Patients with incident elevated SPAP were older (66 – 12 vs 60 – 11 years, p [
0.001), had more systemic hypertension (58% vs 30%, p <0.001) and lower LVEF (43 – 9%
vs 48 – 8%, p <0.001) than their counterparts. Left atrial volume was larger (23 – 11 vs 18 –
6 ml/m2, p [ 0.006), and moderate to severe mitral regurgitation was more prevalent in
patients with incident elevated SPAP (16% vs 7%, p [ 0.05). Independent correlates of
incident elevated SPAP at 12-month follow-up were age (odds ratio [OR] 1.04, 95% CI 1.01
to 1.08, p [ 0.01), hypertension (OR 2.52, 95% CI 1.23 to 5.14, p [ 0.01), baseline LVEF
(OR 0.94, 95% CI 0.90 to 0.98, p[ 0.003), and baseline left atrial volume (OR 1.08, 95% CI
1.03 to 1.12, p [ 0.001). Incident elevated SPAP was independently associated with all-
cause mortality (hazard ratio 3.84, 95% CI 1.76 to 8.39, p [ 0.001). In conclusion,
although the incidence of elevated SPAP after STEMI is low, its presence is independently
associated with increased risk of all-cause mortality at follow-up.  2016 The Authors.
Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/). (Am J Cardiol 2016;118:326e331)The presence of elevated systolic pulmonary artery
pressure (SPAP) after ST-segment elevation myocardial
infarction (STEMI) has been associated with adverse out-
come.1e3 In addition, elevated SPAP may develop after
STEMI due to increased left ventricular (LV) ﬁlling pres-
sures due to LV systolic and diastolic dysfunction.2e8 The
adoption of primary percutaneous coronary intervention
(PCI) as standard treatment of STEMI has led to limited
infarct size, more preserved LV systolic and diastolic
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0.1016/j.amjcard.2016.05.008follow-up,9 which may result in lower incidence of
increased SPAP. However, this hypothesis remains unex-
plored. Furthermore, little is known about the development
and the prognostic implications of incident elevated SPAP
during follow-up after STEMI. Accordingly, the aims of the
present evaluation were threefold (1) to assess the preva-
lence of elevated SPAP at baseline and at 12-month follow-
up in patients with STEMI treated with primary PCI; (2) to
assess contributing factors to the development of incident
elevated SPAP during follow-up; and (3) to evaluate the
prognostic implications of incident elevated SPAP during
follow-up after STEMI.Methods
The present evaluation included 705 patients with a ﬁrst
STEMI treated with primary PCI and with available echo-
cardiograms at baseline and 12-month follow-up, in which
measurement of SPAP was feasible. Patients with previous
MI were excluded. Other exclusion criteria were out-of-
hospital cardiac arrest, severe chronic obstructive pulmo-
nary disease, lobectomy, preexisting pulmonary arterialccess article www.ajconline.org
Table 1
Baseline characteristics
Variable Overall population
(n ¼ 705)
Systolic pulmonary arterial pressure
at follow-up
P*
Normal
(n ¼ 648†)
Elevated
(n ¼ 38†)
Age (years) 60  12 60  11 66  12 0.001
Men 529 (75%) 485 (75%) 29 (76%) 0.84
Current smoker 353 (50%) 325 (50%) 17 (45%) 0.51
Diabetes mellitus 59 (8%) 56 (9%) 2 (5%) 0.76
Family history of coronary artery disease 320 (45%) 294 (45%) 20 (53%) 0.41
Hypercholesterolemia 126 (18%) 116 (18%) 8 (21%) 0.63
Hypertension 222 (32%) 193 (30%) 22 (58%) <0.001
Culprit coronary artery
Left anterior descending 329 (47%) 298 (46%) 15 (39%) 0.52
Right 270 (38%) 251 (39%) 17 (45%) 0.38
Left circumﬂex 105 (15%) 99 (15%) 5 (13%) 0.77
Multivessel coronary disease 335 (48%) 304 (47%) 19 (50%) 0.71
Thrombolysis In Myocardial Infarction 2 e 3 ﬂow 698 (99%) 642 (99%) 38 (100%) 1.00
Killip class 2 20 (3%) 18 (3%) 2 (5%) 0.31
Peak creatine phosphokinase level (U/L) 2,107  1,959 2,042  1,906 2,304  2,201 0.42
Peak troponin T level (mg/L) 5.6  5.4 5.3  5.1 7.0  7.5 0.06
Medication at discharge
Angiotensin-converting enzyme -inhibitors / angiotensin receptor blockers 691 (98%) 636 (98%) 37 (97%) 0.53
Antiplatelets 705 (100%) 648 (100%) 38 (100%) 1.00
Beta-blockers 666 (95%) 613 (95%) 35 (92%) 0.51
Statins 701 (99%) 644 (99%) 38 (100%) 1.00
Echocardiography
Left ventricular end-systolic volume (mL/m2) 28  9 28  9 31  13 0.14
Left ventricular end-diastolic volume (mL/m2) 52  14 52  14 53  17 0.81
Left ventricular ejection fraction (%) 47  9 48  8 43  9 <0.001
Wall motion score index 1.44  0.28 1.43  0.27 1.49  0.27 0.24
Mitral inﬂow peak early velocity/mitral inﬂow peak late velocity ratio 0.99  0.37 0.97  0.36 1.03  0.46 0.33
Deceleration time (ms) 207  71 209  71 192  73 0.17
Mitral inﬂow peak early velocity/mitral annular peak early velocity ratio 13  5 13  5 14  4 0.12
Left atrial volume (mL/m2) 18  7 18  6 23  11 0.006
Moderate to severe mitral regurgitation grade, n (%) 51 (7%) 43 (7%) 6 (16%) 0.05
Tricuspid annulus diameter (cm) 3.7  0.6 3.7  0.6 3.8  0.6 0.17
Right ventricular end-diastolic area (cm2) 18.1  4.3 18.2  4.3 18.4  4.5 0.80
Right ventricular end-systolic area (cm2) 10.4  2.9 10.4  2.9 10.6  3.2 0.63
Tricuspid annular plane systolic excursion (mm) 19  3.3 19  3.3 20  3.6 0.06
Right atrial area (cm2) 13.1  3.9 13.0  3.7 13.6  5.1 0.48
Moderate to severe tricuspid regurgitation grade, n (%) 41 (6%) 31 (5%) 4 (11%) 0.12
Estimated systolic pulmonary arterial pressure (mm Hg) 24.9  8.9 24.2  8.3 26.7  6.8 0.07
Data are presented as mean value  SD and as frequencies and percentages.
* p Values are provided for the comparisons of patients with and without incident elevated systolic pulmonary arterial pressure (SPAP) at 12-month follow-
up (deﬁned as SPAP 36 mm Hg).
† For this comparison, patients with elevated SPAP at both baseline and 12-month follow-up were excluded (n ¼ 19).
Coronary Artery Disease/Elevated SPAP in STEMI 327hypertension, congenital heart disease, and preexisting
severe valvular heart disease. Finally, patients with rein-
farction before the 12-month echocardiogram were
excluded. For this retrospective analysis of clinically ac-
quired data, the institutional review board waived the need
of patient written informed consent.
Images were obtained with the patient at rest in the left
lateral decubitus position using a commercially available
system (Vivid 7 and E9; General Electric-Vingmed, Horten,
Norway). Data were acquired with 3.5 MHz or M5S
transducers in the standard parasternal and apical views.
Standard M-mode, 2-dimensional, color, pulsed, and
continuous wave Doppler images were obtained and stored
in cineloop format. Data analysis was performed ofﬂine withcommercially available postprocessing data software
(EchoPAC version 111.0.0; General Electric-Vingmed).
SPAP was calculated by adding right ventricular (RV)
pressure to right atrial pressure. RV pressure was estimated
by calculating the systolic pressure gradient between the RV
and right atrium by the maximum velocity of the regurgitant
jet using the modiﬁed Bernoulli equation.10 Right atrial
pressure was estimated by measuring the diameter and the
inspiratory collapse of the vena cava inferior.10 Further-
more, RV dimensions and function were evaluated by
measuring RV end-diastolic area, RV end-systolic area,
right atrial area, and tricuspid annular plane systolic
excursion in the apical 4-chamber view.10 In addition, LV
volumes and function were assessed by measuring the LV
Figure 1. Prevalence of elevated systolic pulmonary arterial pressure
(SPAP; deﬁned as SPAP 36 mm Hg) at baseline and at 12-month follow-
up after STEMI. The prevalence of newly developed elevated SPAP at
12 months (incident elevated SPAP) is 5% (n ¼ 38). The absolute change in
mean SPAP from baseline to 12-month follow-up is also presented in the
ﬁgure as mean  standard error. st. error ¼ standard error.
328 The American Journal of Cardiology (www.ajconline.org)end-systolic and end-diastolic volumes, indexed to the body
surface area, and LV ejection fraction (LVEF) using the
biplane Simpson’s method.11 The wall motion score index
was calculated as recommended by current guidelines. LV
diastolic function was evaluated by obtaining peak early (E)
and late (A) diastolic velocities and E-wave deceleration
time. E0 was assessed with tissue Doppler imaging at the
septal side of the mitral annulus in the apical 4-chamber
view, and E/E0 ratio was calculated.12 Moreover, accord-
ing to the biplane Simpson’s technique maximal left atrial
volume was measured in the apical 4-chamber and
2-chamber views and indexed to the body surface area.11
The presence of signiﬁcant valvular heart disease was
evaluated according to the current guidelines.11,13,14
After discharge, patients were followed up according to
the institutional MISSION! protocol.15 The study end point
was all-cause mortality with the initial time set at the 12-
month echocardiogram. Survival status was obtained
through municipal civil registries. Lost to follow-up was
considered in patients without data on the last 6 months.
Data of these patients were included up to the last date of
follow-up.
Continuous data are reported as mean  SD or SEM,
where appropriate, and categorical data as frequencies and
percentages. Elevated SPAP was deﬁned as 36 mm Hg.16
The prevalence of elevated SPAP was assessed at baseline
and at 12-month follow-up. Incident elevated SPAP at 12-
month follow-up was deﬁned as normal SPAP at baseline
and elevated SPAP at the 12-month echocardiogram.
Thereafter, patients with elevated SPAP at both baseline and
12-month follow-up were excluded from further analyses.
Subsequently, the patient population was divided according
to the presence or absence of incident elevated SPAP at 12-
month follow-up. Differences in baseline clinical and
echocardiographic characteristics between patients with and
without incident elevated SPAP were assessed using the
Student t test and chi-square test. Univariate and multivar-
iate logistic regression analyses were performed to identify
independent baseline clinical and echocardiographic corre-
lates of incident elevated SPAP. Thereafter, cumulative
survival rates were assessed using the KaplaneMeier
method. The initial time was set at the 12-month echocar-
diogram, and the end of follow-up was set at the date ofdeath from any cause or censored at December 31, 2012.
Using a log-rank test, differences in cumulative survival
rates in patients with or without incident elevated SPAP
were assessed. Finally, univariate and multivariate Cox
proportional hazards analyses were performed to identify
clinical and 12-month echocardiographic determinants of
all-cause mortality, and the relative risks were expressed
as hazard ratios with associated 95% conﬁdence intervals.
Clinical and echocardiographic relevant univariate variables
with a p <0.10 were included in a multivariate Cox
regression model. For multivariate models, all univariate
variables with a p <0.10 were included in a multivariate
logistic regression model. A correlation coefﬁcient of <0.7
was set to avoid multicollinearity between univariate cor-
relates. To avoid multicollinearity between univariate pa-
rameters, a correlation coefﬁcient of <0.7 was set. In
addition, LV end-diastolic volume, LV end-systolic volume,
and LVEF were not included in the same model to avoid
collinearity. Likewise, different parameters of diastolic
function were not included in the same model. A p value
<0.05 was considered statistically signiﬁcant, and all tests
were 2 sided. All statistical analyses were performed with
SPSS software, version 20.0 (SPSS Inc., Chicago, Illinois).
Results
A total of 705 patients with a ﬁrst STEMI treated with
PCI were evaluated. Table 1 summarizes the baseline clin-
ical and echocardiographic characteristics of the patient
population. In the overall population, there were no signif-
icant changes in SPAP at baseline and 12-month follow-up
(25  9 mm Hg and 25  8 mm Hg, respectively). The
prevalence of elevated SPAP (deﬁned as 36 mm Hg) at
baseline and 12-month follow-up was 10% (n ¼ 71) and 8%
(n ¼ 57), respectively (Figure 1). Nineteen patients with
elevated SPAP at baseline and 12-month follow-up were
hereafter excluded from further analyses (Figure 1). The
incidence of elevated SPAP at follow-up was 5% (n ¼ 38)
and were hereafter referred to as patients with incident
elevated SPAP.
Baseline characteristics of patients with and without
incident elevated SPAP are presented in Table 1. Patients
with incident elevated SPAP were signiﬁcantly older and
had a higher prevalence of hypertension in comparison to
patients with normal SPAP. Both groups were comparable
for other cardiovascular risk factors, culprit vessel and mean
peak cardiac enzymes although patients with incident
elevated SPAP tended to show higher peak cardiac troponin
T levels. At discharge, there was no difference in use of
medication (Table 1).
Regarding echocardiographic characteristics, patients
with incident elevated SPAP showed a lower LVEF and
larger left atrial volumes at baseline compared with their
counterparts (Table 1). Furthermore, in patients with inci-
dent elevated SPAP, there was a higher prevalence of
moderate to severe mitral regurgitation grade compared with
the group with normal SPAP. There were no signiﬁcant
differences in RV volumes and function at baseline between
the 2 groups (Table 1).
Table 2 demonstrates the univariate and multivariate lo-
gistic regression analyses to identify correlates of incident
Table 2
Determinants of incident elevated systolic pulmonary arterial pressure at 12-month follow-up after ST-segment elevation myocardial infarction
Variable Univariate analysis Multivariate analysis
Odds
ratio
95%
Conﬁdence
interval
P Odds
ratio
95%
Conﬁdence
interval
P
Age (years) 1.05 1.02 e 1.09 0.001 1.04 1.01 e 1.08 0.01
Hypertension 3.23 1.66 e 6.29 0.001 2.52 1.23 e 5.14 0.01
Peak troponin T level (mg/L) 1.05 0.99 e 1.10 0.07 1.02 0.96 e 1.08 0.58
Left ventricular end-systolic volume (mL/m2) 1.03 1.00 e 1.06 0.05
Left ventricular ejection fraction (%) 0.93 0.90 e 0.97 0.001 0.94 0.90 e 0.98 0.003
Moderate to severe mitral regurgitation grade 2.64 1.05 e 6.65 0.04
Left atrial volume (mL/m2) 1.10 1.05 e 1.14 <0.001 1.08 1.03 e 1.12 0.001
Tricuspid annular plane systolic excursion (mm) 1.10 0.99 e 1.22 0.06
Elevated systolic pulmonary arterial pressure (SPAP) was deﬁned as SPAP 36 mm Hg at 12 months follow-up.
Figure 2. KaplaneMeier survival curves for patients with incident elevated
SPAP (solid line) and without elevated SPAP (dotted line) at 12 months
(elevated SPAP was deﬁned as 36 mm Hg). The initial time was set at the
12-month echocardiogram.
Coronary Artery Disease/Elevated SPAP in STEMI 329elevated SPAP at 12-month follow-up. Age, hypertension,
peak cardiac troponin T level, LVEF, and left atrial volume
(all with p <0.10 at univariate analysis) were included in the
ﬁnal multivariate model. Independent determinants of inci-
dent elevated SPAP were age, hypertension, LVEF, and left
atrial volume (Table 2).
During a median follow-up of 62 months (interquartile
range 29 to 75), 43 patients (6%) died. The initial time of
follow-up was set at the 12-month echocardiogram. There
were no patients lost to follow-up. The cumulative survival
rates in the patient group with normal SPAP were 99%,
98%, and 96% at 1, 3, and 5 years of follow-up, respec-
tively. In comparison, the patient group with incident
elevated SPAP had signiﬁcantly worse outcome with sur-
vival rates at 1 year of 97%, at 3 years of 89%, and at
5 years follow-up of 76% (log-rank p <0.001, Figure 2).
Univariate and multivariate Cox regression analyses were
performed to determine the prognostic value of incident
elevated SPAP adjusted for other clinical and echocardio-
graphic parameters. Signiﬁcant univariate determinants of
all-cause mortality are summarized in Table 3. Age, multi-
vessel disease, LVEF, left atrial volume, and SPAP
36 mm Hg were introduced in a multivariate model
(Table 3). In the multivariate model, age, LVEF, and SPAP
36 mm Hg were independently associated with all-cause
mortality (Table 3). In addition, incident elevated SPAP at
12-month follow-up was associated with a fourfold adjustedincreased risk of all-cause mortality compared to patients
with normal SPAP (Table 3).Discussion
The present study demonstrated that the incidence of
elevated SPAP after STEMI is low. Independent correlates
of incident elevated SPAP were age, hypertension, baseline
LVEF, and left atrial volume. Importantly, the development
of elevated SPAP after STEMI was independently associ-
ated with increased risk of all-cause mortality.
The prevalence of elevated SPAP after acute MI ranges
from 21% to 45%, depending on the deﬁnition used.1e3,17
The heterogeneous populations included in previous
studies (STEMI and non-STEMI patients who were treated
with either thrombolysis or PCI) may explain the disparate
prevalences. In contrast, the present study, evaluating only
STEMI patients treated with primary PCI, showed a 10%
prevalence of elevated SPAP after STEMI. Primary PCI has
demonstrated to limit infarct size and preserve LV func-
tion.18,19 Since both LV systolic and diastolic dysfunction
may lead to increased LV ﬁlling pressures and elevated
SPAP,2e8 the systematic use of primary PCI may result in a
decreased prevalence of elevated SPAP. Mutlak et al3 re-
ported that in 1,054 patients (82% STEMI) admitted with
acute coronary syndrome, the prevalence of SPAP >35 mm
Hg measured by echocardiography was 45%. Patients with
low SPAP were signiﬁcantly more often treated with
percutaneous coronary revascularization compared to pa-
tients with elevated SPAP. Similar results were also
observed in a series of 536 acute MI patients where the
prevalences of moderately elevated (31 to 55 mm Hg) and
severely elevated RV systolic pressure (>55 mm Hg) were
54% and 21%, respectively.2 Patients with low RV systolic
pressures were more often treated with primary PCI,
whereas patients who received thrombolytic therapy had
similar values of RV pressures than those who did not
receive any revascularization therapy. The inclusion of only
STEMI patients treated with primary PCI in the present
study may have led to a lower prevalence of elevated SPAP
directly after STEMI. Furthermore, the exclusion of patients
who did not survive the ﬁrst year after the index STEMI
may be an important bias since less sicker patients may have
Table 3
Predictors of all-cause mortality after ST-segment elevation myocardial infarction
Variable Univariate analysis Multivariate analysis
Hazard ratio 95% Conﬁdence
interval
P Hazard ratio 95% Conﬁdence
interval
P
Age (years) 1.09 1.06 e 1.12 <0.001 1.08 1.04 e 1.11 <0.001
Diabetes Mellitus 2.08 0.93 e 4.69 0.08
Multivessel disease 2.08 1.12 e 3.86 0.02 1.33 0.73 e 2.44 0.36
Peak cardiac troponin T level (mg/L) 1.04 0.99 e 1.08 0.10
Angiotensin-converting enzyme -inhibitors / Angiotensin receptor blocker 0.25 0.08 e 0.81 0.02
Left ventricular ejection fraction (%) 0.97 0.94 e 1.00 0.07 0.96 0.93 e 0.99 0.01
Wall motion score index 2.88 1.42 e 5.84 0.003
Mitral inﬂow peak early velocity /mitral inﬂow peak late velocity ratio 1.03 1.01 e 1.05 0.009
Mitral inﬂow peak early velocity /mitral annular peak early velocity ratio 1.05 1.02 e 1.08 <0.001
Moderate to severe mitral regurgitation grade 2.57 1.14 e 5.80 0.02
Left atrial volume (mL/m2) 1.04 1.01 e 1.08 0.02 0.99 0.96 e 1.04 0.91
Tricuspid annular plane systolic excursion (mm) 0.92 0.84 e 1.00 0.06
Systolic pulmonary arterial pressure 36 mmHg 6.21 3.05 e 12.67 <0.001 3.84 1.76 e 8.39 0.001
330 The American Journal of Cardiology (www.ajconline.org)been selected, as reﬂected by a relatively preserved LVEF.
Together with the exclusion of other co-morbidities that
may be associated with increased SPAP (i.e., chronic pul-
monary obstructive disease), this may explain the relatively
low prevalence of increased SPAP.
Little is known about the development of elevated SPAP
during follow-up after STEMI, especially in patients treated
with primary PCI. In the present evaluation, 8% of the pa-
tient population had elevated SPAP at 12-month follow-up.
Of these, 38 patients (5% of the total population) had newly
developed elevated SPAP (or incident elevated SPAP). In-
dependent associates of incident elevated SPAP at 12-month
follow-up were age, hypertension, lower LVEF, and higher
left atrial volume as a parameter of diastolic function. The
association between age and reduced LVEF with the pres-
ence of elevated SPAP directly measured after acute MI has
been previously described.3 Furthermore, previous studies
showed a correlation between the presence of LV diastolic
dysfunction and post-MIeelevated SPAP.2,3,17 However, it
should be noted that these studies evaluated the prevalence
of elevated SPAP directly measured after acute MI, whereas
the present study assessed the prevalence of elevated SPAP
at 12-month follow-up. Andersen et al20 showed that in
patients with recent MI and preserved LVEF, those with LV
diastolic dysfunction (reﬂected by increased E/E0 ratio and
left atrial volume) had higher values of invasively measured
SPAP compared to patients without diastolic dysfunction.
Interestingly, patients with recent MI and LV diastolic
dysfunction had a higher prevalence of hypertension
compared to patients without diastolic dysfunction, which
may contribute to increased LV afterload and left atrial
pressure.20 In line, the present study showed that hyper-
tension was an independently associated with incident
elevated SPAP. Furthermore, patients with elevated SPAP
had more frequently signiﬁcant mitral regurgitation than
their counterparts although the difference was not statisti-
cally signiﬁcant. Nevertheless, this may have contributed to
the elevated SPAP.
The presence of elevated SPAP has been associated with
increased risk of mortality and morbidity in patients afterSTEMI. Mutlak et al3 reported an increased risk for read-
mission for heart failure at 1 year follow-up in patients with
SPAP >35 mm Hg measured after acute MI. Similarly,
Carasso et al1 demonstrated that patients who died within
30 days after acute MI or acute coronary syndrome had
signiﬁcantly higher SPAP compared with patients without
event. Moller et al2 conﬁrmed these results by showing that
an increase in RV systolic pressure was an independent
predictor of mortality after adjusting for conventional risk
factors including LV diastolic and systolic function. The
present study provides novel evidence by reporting on the
development of new elevated SPAP after STEMI and its
association with a fourfold increased risk for all-cause
mortality after adjusting for important clinical and echo-
cardiographic parameters. These results suggest that during
1-year follow-up, routine echocardiographic surveillance of
patients with ﬁrst STEMI treated by PCI may help to
identify those subjects who are at risk for developing
increased SPAP. Furthermore, additional testing including
exercise echocardiography to evaluate pulmonary hyper-
tension may a valuable tool in patients with relatively pre-
served LVEF and disproportionate heart failure symptoms.
A previous study has shown that exercise-induced pulmo-
nary hypertension was associated with 5.3-fold increased
risk for cardiovascular mortality in patients with secondary
mitral regurgitation.21 In the present study, patients with
increased SPAP had more frequently signiﬁcant mitral
regurgitation. Exercise echocardiography would have hel-
ped to identify a larger number of patients with increased
SPAP particularly in the subgroup of patients with more
than mild secondary mitral regurgitation.
Some limitations should be acknowledged. The present
single-center study was retrospective. However, the present
evaluation consisted of a large contemporary cohort of pa-
tients with STEMI treated according to the current guide-
lines. Although patients with known clinical conditions that
might affect SPAP independently of the MI were excluded
by careful clinical review, further evaluation by means of
functional lung tests, for example, were not performed and
some patients may have been underdiagnosed. Furthermore,
Coronary Artery Disease/Elevated SPAP in STEMI 331changes in hemodynamics during the acute phase and
follow-up may have had an inﬂuence on the prevalence and
incidence of elevated SPAP. Data on the use of loop di-
uretics and/or aldosterone antagonists were not systemati-
cally collected. However, the analyses were corrected for
other load-dependent parameters.
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